ALX Oncology Holdings Inc (ALXO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.01-0.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ALXO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 117.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ALXO — credit agreement
Dated 2026-06-26
Entry into a Material Definitive Agreement. On June 25, 2026, ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), entered into a loan and security agreement (the “Loan Agreement”) among HSBC Ventures USA Inc., as lender, ALX Oncology Inc., a Delaware corporation (“ALX”), as borrower, and the Company and ALX Oncology Limited, as guarantors. The Loan Agreement provides for a secured multi-tranche term loan facility in an aggregate principal amount of up to $50,000,000, of which…
Why it matters: Keeping cash reserves is important for funding clinical trials. Not enough money could delay or stop development.
Worry ifCash reserves are over $150 million. This ensures funding for operations until Q1 2027.
Less concerning ifCash reserves drop below $100 million. This raises concerns about funding for clinical trials.
Why it matters: Earnings results will show if the company can make more money after a recent miss.
Watch forEarnings per share (EPS) is better than analysts expected. This shows better financial health.
Also watch forEarnings miss expectations again. This shows ongoing financial struggles.
Why it matters: Advancing clinical trials is key for growth. Success could lead to new revenue streams.
Supportive ifCompany shares good news from an important clinical trial.
Worry ifCompany has delays or issues in its clinical trials.
Why it matters: Updates on cash position will show if ALX can fund operations through its clinical trials. A strong cash position supports ongoing development.
Watch forCash position is above $150 million after the loan agreement.
Also watch forCash position drops below $100 million, raising funding concerns.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$243 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $953 loss on $10,000 · 9.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,046 loss on $10,000 · 50.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Earnings results will show how well ALXO is managing its resources and growth plans.
Worry ifEarnings show revenue growth or smaller losses compared to earlier quarters.
Less concerning ifEarnings do not meet expectations or show bigger losses.
Why it matters: Maintaining sufficient cash is vital for funding ongoing clinical trials. A drop in cash could signal financial trouble.
Worry ifCash, cash equivalents, and investments are over $150 million.
Less concerning ifCash balance drops below $100 million, raising concerns about funding.
Why it matters: In mid-2027, data from 80 patients will show how well evorpacept works for HER2-positive breast cancer.
Supportive ifTopline data readout confirms positive results from the ASPEN-09-Breast trial.
Worry ifThe data shows that evorpacept did not work well in the trial.
Why it matters: Changes in leadership can change strategy and how things are done. This affects the future.
Watch forGood performance results or new plans announced with new leaders.
Also watch forLook for weak results or mistakes after changes in leadership.
Why it matters: Safety data will indicate if ALX2004 can move forward in development. Positive safety results can lead to further trials.
Supportive ifALX2004 safety data shows it is well tolerated. There are no serious side effects.
Worry ifSafety data shows serious side effects. This stops further development.
Why it matters: This data will show how well evorpacept works in treating HER2-positive breast cancer. Positive results could boost confidence in the drug's potential.
Supportive ifData from 80 patients shows good results for evorpacept in HER2-positive breast cancer.
Worry ifData shows poor results or delays past mid-2027.
Why it matters: Updates on cash reserves will show if ALX can fund operations into 2027. A strong cash position supports ongoing trials.
Watch forCash and cash equivalents are over $150 million. This means funding is enough through 2027.
Also watch forCash and cash equivalents fall below $150 million. This raises worries about funding.